Mutant EGFR inhibitor - CAS 1421373-62-7
Catalog number:
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Publictions citing BOC Sciences Products
  • >> More
Mutant EGFR inhibitor
1.EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature.
Yang Y1, Zhang B2, Li R1, Liu B1, Wang L1. Oncol Lett. 2016 May;11(5):3546-3550. Epub 2016 Apr 5.
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are considered to be effective treatments for advanced non-small cell lung cancer (NSCLC) patients with sensitizing EGFR mutations, including exon 19 deletion and exon 21 L858R mutations. However, with the development of EGFR mutation detection assays, patients with complex EGFR mutations are emerging, and their response to EGFR-TKIs remains unclear. The present study reports a case of a 62-year-old, non-smoking female patient with advanced NSCLC, presenting with concurrent EGFR 19+21 sensitizing mutations, who had a poor response to the first-line EGFR-TKI erlotinib and succumbed 5 months subsequent to diagnosis. Furthermore, the present study performed a literature review, and 18 patients with complex EGFR 19+21 mutations that had received EGFR-TKIs were identified. The majority of these patients responded well to EGFR-TKIs. To the best of our knowledge, the present case is the first to report a patient with lung adenocarcinoma with complex EGFR 19+21 sensitizing mutations that had a poor clinical response to a first-line EGFR-TKI.
2.The Frequency of EGFR Mutation in Lung Adenocarcinoma and the Efficacy of Tyrosine Kinase Inhibitor Therapy in a Hungarian Cohort of Patients.
Sárosi V1, Balikó Z1, Smuk G2, László T2, Szabó M1, Ruzsics I1, Mezősi E3. Pathol Oncol Res. 2016 Apr 22. [Epub ahead of print]
In the last decades new therapeutic drugs have been developed for the treatment of non-small cell lung cancer (NSCLC) patients. Tyrosine kinase inhibitors (TKIs) significantly increase the progression free survival (PFS) of patients with NSCLC carrying epidermal growth factor receptor (EGFR) mutations. This type of lung cancer occurs mainly among non-smoking women and Asian origin. However, the new ESMO guideline recommends EGFR mutation analysis in every patient with NSCLC, because in patients with activating EGFR mutation, TKIs should be considered as first line therapy. In our recent work, we analyzed data of patients with EGFR-mutant adenocarcinoma from January 2009. The number of patients investigated was 446, among them 44 cases were positive for EGFR mutation. The ratio of positive cases was 9.86 % that is lower than the average mutation rate in Europe and much lower than that found in Asia. The exon 19 deletion was detected in 61.
3.Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors.
Xiao Q1, Qu R2, Gao D1, Yan Q1, Tong L2, Zhang W1, Ding J2, Xie H3, Li Y4. Bioorg Med Chem. 2016 Apr 19. pii: S0968-0896(16)30273-5. doi: 10.1016/j.bmc.2016.04.032. [Epub ahead of print]
To overcome the drug-resistance of first generation EGFR inhibitors and the nonselective toxicities of second generation inhibitors among NSCLC patients, a series of 5-(methylthio)pyrimidine derivatives were discovered as novel EGFR inhibitors, which harbored not only potent enzymatic and antiproliferative activities against EGFRL858R/T790M mutants, but good selectivity over wide-type form of the receptor. This goal was achieved by employing structure-based drug design and traditional optimization strategies, based on WZ4002 and CO1686. These derivatives inhibited the enzymatic activity of EGFRL858R/T790M mutants with IC50 values in subnanomolar ranges, while exhibiting hundreds of fold less potency on EGFRWT. These compounds also strongly inhibited the proliferation of H1975 non-small cell lung cancer cells bearing EGFRL858R/T790M, while being significantly less toxic to A431 human epithelial carcinoma cells with overexpressed EGFRWT. The EGFR kinase inhibitory and antiproliferative activities were further validated by Western blot analysis for activation of EGFR and the downstream signaling in cancer cells.
4.Pretreatment neutrophil-lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor-mutant non-small cell lung cancer patients treated with tyrosine kinase inhibitors.
Sim SH1, Beom SH1, Ahn YO2, Keam B3, Kim TM3, Lee SH3, Kim DW3, Heo DS3. Thorac Cancer. 2016 Mar;7(2):161-6. doi: 10.1111/1759-7714.12304. Epub 2015 Aug 28.
BACKGROUND: The neutrophil-lymphocyte ratio (NLR) is a marker of poor prognosis in lung cancer patients. However, previous data have been based on an heterogeneous population of lung cancer patients and various treatments. In this study, we evaluate the prognostic value of NLR in an homogeneous population of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related EGFR Products

(CAS: 1446090-77-2)

BGB-283 is a selective Epidermal growth factor receptor and Proto oncogene protein b raf inhibitor under the development of BeiGene. BGB-283 shows antitumor act...

CAS 1204313-51-8 Icotinib (Hydrochloride)

Icotinib (Hydrochloride)
(CAS: 1204313-51-8)

CAS 366017-09-6 Mubritinib

(CAS: 366017-09-6)

Mubritinib, also known as TAK-165, is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer. It completed phase I clinic...

CAS 871026-44-7 TAK-285

(CAS: 871026-44-7)

TAK-285 is a novel dual erbB protein kinase inhibitor that specifically targets human epidermal growth factor receptor (EGFR) and HER2. Methods: TAK-285 is curr...

CAS 231277-92-2 Lapatinib

(CAS: 231277-92-2)

Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively.

CAS 1374640-70-6 CO1686

(CAS: 1374640-70-6)

CAS 136831-48-6 RG13022

(CAS: 136831-48-6)

RG13022, a non-phenolic tyrphostin analog, is an epidermal growth factor (EGF) receptor tyrosine kinase inhibitor with potential antiproliferative effect.

CAS 196612-93-8 Falnidamol

(CAS: 196612-93-8)

Falnidamol, also known as BIBX 1382, is a pyrimido-pyrimidine with antitumor activity. BIBX 1382 inhibits the intracellular tyrosine kinase domain of the Epider...

CAS 1092364-38-9 Poziotinib

(CAS: 1092364-38-9)

Poziotinib, also known as HM781-36B and NOV120101, is an orally bioavailable, quinazoline-based pan epidermal growth factor receptor (EGFR or HER) inhibitor wit...

CAS 937265-83-3 ARRY-380

(CAS: 937265-83-3)

ARRY-380 is a potent and selective HER2 inhibitor with IC50 of 8 nM, equipotent against truncated p95-HER2, 500-fold more selective for HER2 versus EGFR.

CAS 1557268-88-8 Avitinib maleate

Avitinib maleate
(CAS: 1557268-88-8)

Avitinib maleate, the maleate salt form of avitinib, is a pyrrolopyrimidine-based, irreversible epidermal growth factor receptor (EGFR) mutant-selective inhibit...

CAS 1421373-65-0 AZD-9291

(CAS: 1421373-65-0)

AZD-9291 is a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become ...

(CAS: 1448232-80-1)

Naquotinib is a irreversible, third-generation, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activitywith ...

CAS 850140-72-6 Afatinib

(CAS: 850140-72-6)

Afatinib irreversibly inhibits EGFR/HER2 including EGFR, EGFR(L858R), EGFR(L858R/T790M) and HER2. It is 100-fold more active against Gefitinib-resistant L858R-T...

CAS 859853-30-8 BMS-6690514

(CAS: 859853-30-8)

BMS-690514 is a potent inhibitor of human epidermal growth factor receptor (HER) 1 (EGFR), 2, and 4, and vascular endothelial growth factor receptors (VEGFR) 1-...

(CAS: 1428774-45-1)

PF-06459988 is a third-generation, irreversible epidermal growth factor receptor (EGFR) inhibitor. It can bind to and inhibit mutant forms of EGFR, including th...

CAS 133550-34-2 AG 555

AG 555
(CAS: 133550-34-2)

AG 555 is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (IC50 = 0.7 μM) with 50-fold and >140-fold selectivity over ErbB2 and insulin rec...

CAS 1050500-29-2 AST-1306

(CAS: 1050500-29-2)

AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-ove...

CAS 850140-73-7 Afatinib Dimaleate

Afatinib Dimaleate
(CAS: 850140-73-7)

Afatinib Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, res...

CAS 133550-41-1 AG 556

AG 556
(CAS: 133550-41-1)

AG 556, a dihydroxyphen derivative, has been found to be a EGFR kinase inhibitor that could probably be effective in the study of myocardial infarct and hemodyn...

Chemical Structure

CAS 1421373-62-7 Mutant EGFR inhibitor

Quick Inquiry

Verification code

Featured Items